
PhorMed
OperatingPhormed Inc
Biotech · Century City, CA · Founded 2019
Utilizing gene therapy to target cancer and mutated cells
Financials
FY2017–FY2025 · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 1 earlier year is in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round. Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Dec 31, 2024| Class | Outstanding | Votes / share | Share of total | Last price |
|---|---|---|---|---|
| Common Stock | 53,163,017 | — | 100.0% | $1.00May 2022 |
Shares outstanding over timein today's share terms
Principal holders% as the filing states it, May 19, 2022
- Owned Prof Richard L.40,615,000 Common Stock78.6%of company
Sold to the crowd
- Reg CF · Dec 20192,515,255 shares at $1.00$2.5M· 4,097 investors
- Reg CF · May 2022169,971 shares at $1.00$170K· 207 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
8 people
• 29+ years experience in multiple biotech and pharmaceutical business ventures • 16+ years of executive level experience in Biotech business ventures • Holder of 2 patents Mr. Chang has previously been founder, director, CEO, President, CFO, and/or COO of such biotech companies as Biosuccess Biotech Co. LTD., Rich Pharmaceuticals, Inc., and HypGen, Inc. Mr. Chang started his life-science career as the founder and managing partner of Sun-Rich Chemicals, product development and distribution organization for nutraceuticals. Mr. Chang also has experience in international banking, venture capital, M&A, finance, go-public transactions, and organizational design and operations. Mr. Chang has a Bachelor of Science Degree in Economics from East Carolina University where he focused on accounting and international business.

In loving memory to our dear friend and colleague

• 36+ years experience in Immunology, Cell Biology, Regenerative Medicine, and Tissue Repair • 65+ peer reviewed publications Dr. O'Connell has served as CSO, CMO, Chief Scientist, SVP, and Founder of multiple pharmaceutical and research companies such as Novartis Pharmaceuticals, Vertical Spine, LLC., Cascade Medical Enterprises, and Integrated Communications Corp. (ICC/IPG). He has received numerous research grants and currently holds the position of Adjunct Professor in the Department of Vascular Surgery, Englewood Hospital and Medical Center, Mount Sinai School of Medicine, New York. He received his PhD in immunology and molecular biology from Rutgers University and the University of Medicine and Dentistry of New Jersey at New Brunswick (now Rutgers Medical school).

Mr. Greene has over 23 years experience in Business Development and Marketing, and extensive experience in C-Level Business Development. His experience includes direct B2B sales, Enterprise Software Sales, Business Development and Marketing, as well as IBM Power Systems Sales and management of server and cloud services teams. He has a comprehensive background in the creation and editing of direct marketing content and campaigns. Mr. Greene has a Bachelor of Arts degree in Communications from Muhlenberg College.

Dr. Salvador created and manages a Clinical, Coaching and Organizational Consulting practice, Affiliates in Psychology and Education for over 30 years. She was a principal in the organizational consulting firm of Cogent Resources and has experience in management, business and scientific research experience and psychopharmacology expertise. Prior to her career in Applied Psychology, she worked in Biochemistry research at Cornell Medical School and Pharmacology research at Burroughs Welcome which is now part of GSK. Dr. Salvador received her Doctor of Psychology from Rutgers University in Applied Psychology and a B.S. in the Biological Sciences from New York University. She has expertise and holds a certificate in psychopharmacology, completed a post-doctoral fellowship in Community Systems and a post-doctoral program in Organizational Development and Consultation at the William Alanson White Institute.

• 53+ years of research experience • Inventor and holder of multiple patents • 124 peer-reviewed journal publications • 150+ Scientific Abstracts • Holder of 9 Patents Professor Chang has filed multiple significant patents for the treatment of cancer, infectious disease, hematology, and neurological disorders. Prof. Chang has over 53 years of research experience with such companies as Hoffman-La-Roche, Schering Corp, and Burroughs Wellcome and is a full professor and director of Research at Rutgers University. He successfully launched and completed off IND and IND phase I trials in China and US.

Mr. Davis has over 30 Years experience in corporate and business law and Extensive knowledge of Business and Corporate law. His experience ranges from serving on the Board of Directors of Philter Labs, Inc., and on the Board of Directors and Audit, Compensation and Nominating Committees of Telanetix, Inc. Prior to starting his own practice, Mr. Davis served as General Counsel and an executive officer of Molecular Imaging Corporation, and as in-house counsel for Leap Wireless International, Inc. He also practiced in the Business and Corporate Group in the San Diego office of Luce, Forward, Hamilton & Scripps LLP (now Dentons), a full-service law firm with over 200 attorneys, where he advised both private and public clients. Mr. Davis is licensed to practice law in California, the District of Columbia, and Minnesota. He received his Juris Doctor, Cum Laude, from the University of San Diego, School of Law in 1992. He received his B.A. in Political Science, Cum Laude, from Arizona State University in 1988.
Names and titles as disclosed on StartEngine, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 6 of 7 annual reports (FY2019–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 29 filings on EDGAR- Form C-ARApr 29, 20260001796036-26-000001EDGAR
- Form C/AApr 24, 20250001670254-25-000408EDGAR
- Form C-ARApr 26, 20240001662252-24-000002EDGAR
- Form C/AApr 24, 20240001670254-24-000422EDGAR
- Form C/ADec 15, 20230001670254-23-001146EDGAR
- Form COct 27, 20230001662252-23-000025EDGAR
- Form C-AROct 20, 20230001665160-23-001862EDGAR
- Form C-USep 29, 20220001665160-22-002521EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.